US2023192851A1PendingUtilityA1

Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

Assignee: GREEN CROSS CORPPriority: Oct 20, 2017Filed: Oct 3, 2022Published: Jun 22, 2023
Est. expiryOct 20, 2037(~11.2 yrs left)· nominal 20-yr term from priority
A61K 39/00C07K 16/2809A61P 35/00C07K 2317/33C07K 2317/24C07K 2317/56
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An anti-CD3 antibody and a pharmaceutical composition, and their uses are disclosed. The anti-CD3 antibody are useful for treating or preventing cancer. The antibody has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.

Claims

exact text as granted — not AI-modified
1 . A method for treating cancer in a subject, comprising administering an effective amount of an antibody or an antigen-binding fragment thereof, said antigen or antigen-binding fragment thereof comprising:
 (a-1) a light chain variable domain (VL domain) comprising the amino acid sequence of SEQ ID NO: 7 or 8; and   (a-2) a heavy chain variable domain (VH domain) comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, or 21, or   (b-1) a light chain variable domain (VL domain) comprising the amino acid sequence of SEQ ID NO: 15 or 16; and   (b-2) a heavy chain variable domain (VH domain) comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, or 25,   wherein the VL domain of (a-1) and (b-1) comprises complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 29, CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and CDR3 comprising the amino acid sequence of SEQ ID NO: 31; and   wherein the VH domain of (a-2) and (b-2) comprises complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 32, CDR2 comprising the amino acid sequence of SEQ ID NO: 33, and CDR3 comprising the amino acid sequence of SEQ ID NO: 34.   
     
     
         2 . The method of  claim 1 , wherein the cancer is pancreatic cancer, liver cancer, gastric cancer, lung cancer, colorectal cancer, rectal cancer, thyroid cancer, esophageal cancer, kidney cancer, bladder cancer, prostate cancer, cervical cancer, breast cancer, blood cancer, skin cancer, epithelial cancer, brain cancer, central nerve system cancer, or ovarian cancer. 
     
     
         3 . The method of  claim 1 , wherein the antibody is a humanized antibody.

Join the waitlist — get patent alerts

Track US2023192851A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.